Fig. 4

SOX4 increases the susceptibility of breast cancer cells to paclitaxel. a MTT assay showing cell viability in response to paclitaxel (PTX) after 48 h treatment. The data are presented as the mean ± s.d. of sextuple wells. Unpaired two-tailed t-test: ***p < 0.001. b Bioluminescent imaging of tumor growth 14 days after treatment with Paclitaxel. 5 × 10⁶ cells (MDA-MB-231-VECT or MDA-MB-231-SOX4) were injected into the mammary fat pad of SCID mice in 5 groups. Three weeks later (day 0), the tumor-bearing mice were treated with paclitaxel (PTX) or PBS. The treatment was repeated at day 7 and the tumors were examined using bioluminescent imaging at day 14. c Statistical analysis of results in b. The data are presented as the mean ± s.d. of 5 mice. Unpaired two-tailed t-test: *p < 0.05